Drug Trial Radar · NCT03449381
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
266
Actual
Start
Jun 20, 2018
Primary completion
Nov 13, 2025
Study completion Nov 13, 2025
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Feb 28, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with different types of advanced cancer (solid tumors). The purpose of this study is to find out the most suitable dose of BI 907828 (brigimadlin) the participants can tolerate. The most suitable dose is used in the second part to find out whether brigimadlin makes tumors shrink. In this study, brigimadlin is given to humans for the first time. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. Brigimadlin is taken as a tablet. Participants either take a dose of brigimadlin on one day every 3 weeks or on two days every 4 weeks. The participants are in the study for as long as they benefit from and can tolerate treatment. The doctors regularly check the participants' general health during the study.
Conditions
- Neoplasms
Interventions
BI 907828Drug
Film-coated tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia- Maximum tolerated dose (MTD) based on number of patients with dose limiting toxicities (DLTs) during first treatment cycleTime frame: Up to 28 days
- Phase Ib - Progression-free survivalTime frame: Up to 24 months
- Phase Ia - Number of patients with DLTs during first treatment cycle (21 days, Arm A; 28 days, Arm B)Time frame: Up to 28 days
- Phase Ib - Number of patients with DLTs during the first treatment cycleTime frame: Up to 28 days
Locations
27 sites in 11 countries. Site status is shown where the registry gives one.
Sarcoma Oncology Center
Santa Monica, California
Yale University School of Medicine
New Haven, Connecticut
Florida Cancer Specialists-Sarasota-61670
Sarasota, Florida
Norton Cancer Institute, Downtown
Louisville, Kentucky
START Midwest
Grand Rapids, Michigan
Memorial Sloan-Kettering Cancer Center
New York, New York
SCRI Oncology Partners
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
University of Wisconsin
Madison, Wisconsin
Cliniques Universitaires Saint-Luc
Brussels, Belgium
UZ Leuven
Leuven, Belgium
The Ottawa Hospital
Ottawa, Ontario, Canada
Rigshospitalet, København
København Ø, Denmark
Helios Klinikum Berlin-Buch
Berlin, Germany
Universitätsklinikum Köln (AöR)
Cologne, Germany
Universitätsmedizin Göttingen, Georg-August-Universität
Göttingen, Germany
Universitätsklinikum Tübingen
Tübingen, Germany
Sourasky Medical Center
Tel Aviv, Israel
National Cancer Center Hospital
Tokyo, Chuo-ku, Japan
MED POLONIA SP Z O O, Clinical Trials Department,Poznan
Poznan, Poland
Oncology Center-Maria Sklodowska-Curie Institute
Warsaw, Poland
Severance Hospital
Seoul, South Korea
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Clínic de Barcelona
Barcelona, Spain
Fundación Jiménez Díaz
Madrid, Spain
Hospital Clínico de Santiago
Santiago de Compostela, Spain
Karolinska Comprehensive Cancer Center
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.